EVIDENCE. COMPARISONS. CLEAR NEXT STEPS.FOR US CLINIC TEAMS PROCUREMENT RESEARCH
Comparisons

Which supply-route categories should clinics compare side by side?

Dose Diligence research deskSection 03 · Page 2 of 12Last updated 17 Nov 2026

Compare operating models before comparing suppliers. A patient-access programme, a pharmacy and a wholesaler perform different jobs. LillyDirect describes prescription fulfilment through dispensing pharmacies; NovoCare describes third-party providers supporting registration, dispensing and delivery. McKesson separately describes pharmaceutical distribution to settings including physician offices. These are not interchangeable purchasing arrangements. (lilly.com)

The following fit assessments are our recommended starting points, subject to the gates described later.

ArrangementWhat the clinic selects or purchasesWhen it fitsWhat to establish before selection
Manufacturer-linked branded accessA patient prescription and payment pathwaySelf-pay cohorts where published programme terms and an external checkout fit the patient journeyExact product eligibility, dispensing destination, ongoing price, status visibility and support ownership
Licensed pharmacy dispensing approved medicinesA dispensing relationship; potentially integration and support servicesMixed insurance/self-pay populations, multiple medicines, or requirements for negotiated operational reportingActual dispensing entities, payer participation, state permissions, product acceptance and service evidence
Authorised wholesale distribution for clinic stockMedicine inventory and distribution servicesA clinic with a defined, lawful stock-use model and the capability to manage inventoryAccount and product eligibility, title transfer, storage, traceability, credit, returns and allocation
503A patient-specific compoundingAn individually assessed compounded prescriptionA documented patient need that warrants a compliant compounding assessment—not routine price substitutionPrescription requirements, formulation-specific justification, copying restrictions, quality and state requirements
503B outsourcingAn eligible compounded preparation, potentially for office stockA specific outsourcing requirement that satisfies the applicable federal and state conditionsActual preparation and ingredients, bulk-substance eligibility, copying restrictions, facility evidence and intended use
Prescription-routing technologySoftware connecting prescribing and pharmacy workflowsA provider that needs pharmacy choice, exception handling or integration across partnersWhat the platform actually observes, which pharmacies are integrated, data portability and responsibilities

The 503A/503B distinctions above derive from FDA's prescription guidance and statutory framework. The ability of an outsourcing facility to supply qualifying office stock does not establish permission to supply a particular compounded GLP-1 preparation. (fda.gov)

For an evidenced software example, Photon documents prescription routing, pharmacy search, fulfilment-status tracking and webhook updates. That establishes advertised technical capabilities, not pharmacy availability or a measured reduction in your clinic's workload. (photonhealth.com)

Explore the table row by row

A working view of the research

Manufacturer-linked branded access

What the clinic selects or purchases
A patient prescription and payment pathway
When it fits
Self-pay cohorts where published programme terms and an external checkout fit the patient journey
What to establish before selection
Exact product eligibility, dispensing destination, ongoing price, status visibility and support ownership

Sources cited on this page

  1. lilly.com · Source 1 ↗https://www.lilly.com/lillydirect/faq
  2. fda.gov · Source 2 ↗https://www.fda.gov/regulatory-information/search-fda-guidance-documents/prescription-requirement-under-section-503a-federal-food-drug-and-cosmetic-act-guidance-industry
  3. photonhealth.com · Source 3 ↗https://photonhealth.com/faq?utm_source=openai
Section sources →